Case of relentless chronic phase of chronic myeloid leukaemia

Onyee Chan, Hao Chen, Ravitharan Krishnadasan, Faiz Anwer

Research output: Contribution to journalArticle

Abstract

Initial treatment of chronic phase chronic myeloid leukaemia is straightforward in today's era of tyrosine kinase inhibitors. However, managing refractory cases remain a major challenge due to the multiple factors that can influence decision-making, including medication tolerance, disease burden, mutation status, comorbidities, availability of donor, and fitness for an ablative conditioning. We report a male patient presenting with chronic phase chronic myeloid leukaemia who was treated with 5 different tyrosine kinase inhibitors either due to intolerance and/or failed response. He subsequently received 2 haploidentical haematopoietic stem cells transplants before achieving complete remission. This case highlights various treatment options, need for vigilant disease monitoring, and the possibility of complete positive response even after many lines of therapy failure.

Original languageEnglish (US)
Article number215370
JournalBMJ Case Reports
Volume2016
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Protein-Tyrosine Kinases
Hematopoietic Stem Cells
Comorbidity
Decision Making
Therapeutics
Tissue Donors
Transplants
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Case of relentless chronic phase of chronic myeloid leukaemia. / Chan, Onyee; Chen, Hao; Krishnadasan, Ravitharan; Anwer, Faiz.

In: BMJ Case Reports, Vol. 2016, 215370, 01.01.2016.

Research output: Contribution to journalArticle

Chan, Onyee ; Chen, Hao ; Krishnadasan, Ravitharan ; Anwer, Faiz. / Case of relentless chronic phase of chronic myeloid leukaemia. In: BMJ Case Reports. 2016 ; Vol. 2016.
@article{9a678df33bd944fe80e68f210c8e4c40,
title = "Case of relentless chronic phase of chronic myeloid leukaemia",
abstract = "Initial treatment of chronic phase chronic myeloid leukaemia is straightforward in today's era of tyrosine kinase inhibitors. However, managing refractory cases remain a major challenge due to the multiple factors that can influence decision-making, including medication tolerance, disease burden, mutation status, comorbidities, availability of donor, and fitness for an ablative conditioning. We report a male patient presenting with chronic phase chronic myeloid leukaemia who was treated with 5 different tyrosine kinase inhibitors either due to intolerance and/or failed response. He subsequently received 2 haploidentical haematopoietic stem cells transplants before achieving complete remission. This case highlights various treatment options, need for vigilant disease monitoring, and the possibility of complete positive response even after many lines of therapy failure.",
author = "Onyee Chan and Hao Chen and Ravitharan Krishnadasan and Faiz Anwer",
year = "2016",
month = "1",
day = "1",
doi = "10.1136/bcr-2016-215370",
language = "English (US)",
volume = "2016",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Case of relentless chronic phase of chronic myeloid leukaemia

AU - Chan, Onyee

AU - Chen, Hao

AU - Krishnadasan, Ravitharan

AU - Anwer, Faiz

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Initial treatment of chronic phase chronic myeloid leukaemia is straightforward in today's era of tyrosine kinase inhibitors. However, managing refractory cases remain a major challenge due to the multiple factors that can influence decision-making, including medication tolerance, disease burden, mutation status, comorbidities, availability of donor, and fitness for an ablative conditioning. We report a male patient presenting with chronic phase chronic myeloid leukaemia who was treated with 5 different tyrosine kinase inhibitors either due to intolerance and/or failed response. He subsequently received 2 haploidentical haematopoietic stem cells transplants before achieving complete remission. This case highlights various treatment options, need for vigilant disease monitoring, and the possibility of complete positive response even after many lines of therapy failure.

AB - Initial treatment of chronic phase chronic myeloid leukaemia is straightforward in today's era of tyrosine kinase inhibitors. However, managing refractory cases remain a major challenge due to the multiple factors that can influence decision-making, including medication tolerance, disease burden, mutation status, comorbidities, availability of donor, and fitness for an ablative conditioning. We report a male patient presenting with chronic phase chronic myeloid leukaemia who was treated with 5 different tyrosine kinase inhibitors either due to intolerance and/or failed response. He subsequently received 2 haploidentical haematopoietic stem cells transplants before achieving complete remission. This case highlights various treatment options, need for vigilant disease monitoring, and the possibility of complete positive response even after many lines of therapy failure.

UR - http://www.scopus.com/inward/record.url?scp=84976596534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976596534&partnerID=8YFLogxK

U2 - 10.1136/bcr-2016-215370

DO - 10.1136/bcr-2016-215370

M3 - Article

C2 - 27335363

AN - SCOPUS:84976596534

VL - 2016

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

M1 - 215370

ER -